Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Mirabegron/solifenacin as an effective therapeutic option for overactive bladder

May 16, 2013

Fedovapagon effectively reduces nocturia in men with BPH

May 15, 2013

Relypsa completes enrollment in pivotal phase III trial of patiromer

May 14, 2013

Astellas and Drais form new partnership to develop treatment candidate for nocturia

May 8, 2013

Roche patents new CYP11B2 inhibitors

April 22, 2013

Nymox's candidate for BPH shows promising sexual function profile in new study

April 18, 2013

Innovative 3D renal tissue model developed to investigate human disease and toxicity

April 18, 2013

FDA sets PDUFA action date for PA-21

April 16, 2013

Novel trypsin inhibitors for renal disorders patented by Astellas Pharma

April 11, 2013

Encouraging findings from phase IIb study of tarafenacin in overactive bladder

April 11, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...